HIMS Stock Gains as FDA Signals Lifting Peptide Compounding Restrictions
Hims & Hers Health stock rose on reports the FDA is preparing to allow compounding pharmacies to produce previously banned injectable peptides, potentially expanding the telehealth company's operations.